Search results
Results from the WOW.Com Content Network
WuXi PharmaTech was founded in December 2000 in Shanghai by organic chemist Ge Li. [1] [2]The company opened chemistry facilities in Tianjin in 2007. In 2008, WuXi PharmaTech acquired AppTec Laboratory Services Inc., a US-based company founded in 2001 with expertise in medical-device and biologics testing and with facilities in St. Paul, MN; Philadelphia, PA; and Atlanta, GA.
In 2016, WuXi AppTec expanded its presence in the United States by opening a new center of excellence in San Diego, California. [10] This facility was designed to enhance WuXi's capabilities in small molecule screening, discovery biology, and process research and development, while also offering Phase I Good manufacturing practice (GMP) services.
The bill has spurred deep concern among investors, driving a sell-off in the shares of WuXi AppTec when news of its introduction first reached Chinese markets last month. US Senate bill targeting ...
Employees of drugmaker WuXi AppTec, under U.S. scrutiny for its links to the Chinese military, co-invented altitude sickness treatments with People's Liberation Army (PLA) scientists, according to ...
In 2022, the WuXi STA Changzhou production campus initiated oligonucleotide and peptide manufacturing to expand cell and gene therapy advancements. [5] Additionally, the different WuXi AppTec entities are inaccurate in the article. See this source to explain the rename and the correct entities under the WuXi AppTec umbrella. As far as I ...
By Karen Freifeld (Reuters) -The U.S. House of Representatives passed a bill on Monday that aims to restrict business with China's WuXi AppTec, BGI and several other biotech companies on national ...
Abgent is a global biotechnology company based in San Diego, California, US with offices in Maidenhead, UK and Suzhou, China and distributors around the world. Abgent develops antibodies and related agents to study proteins involved in cellular function and disease.
(Reuters) -A new version of a congressional bill that would restrict U.S. business with certain Chinese biotechnology companies including WuXi AppTec and BGI would give U.S. companies until 2032 ...